Droxinavir
From Wikipedia, the free encyclopedia
![]() |
|
Names | |
---|---|
IUPAC name
3-tert-butyl-1-[(2R,3S)-3-[(2S)-3,3-dimethyl-2-[2-(methylamino)acetamido]butyramido]-2-hydroxy-4-phenylbutyl-1-isopentylurea
|
|
Other names
SC 55389A
|
|
Identifiers | |
159910-86-8 ![]() |
|
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL2110878 ![]() |
ChemSpider | 409165 ![]() |
PubChem | 70683043 |
UNII | 3CF21QCB9J ![]() |
|
|
|
|
Properties | |
C29H51N5O4 | |
Molar mass | 533.75 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Droxinavir (also known as SC 55389A) was an experimental protease inhibitor researched by Pharmacia as a treatment for HIV infection. Its research and development was discontinued on March 06, 1995.[1]
References[edit]
- ^ "Drug Profile: Droxinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 23 November 2015.
![]() |
This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |